A Clinical Study on the Efficacy and Safety of Zinc Sulfate Enhancing Toripalimab Combined with Axitinib in the Treatment of Advanced Renal Cell Carcinoma

开始日期2026-08-24

申办/合作机构

华中科技大学同济医学院

[+1]

ChiCTR2600128788

/ Not yet recruiting临床2期IIT

Zinc Sulfate Enhances the Efficacy and Safety of Toripalimab Combined with Disitamab Vedotin in the Treatment of Patients with HER2-Positive Muscle-Invasive Bladder Urothelial Carcinoma

开始日期2026-08-01

申办/合作机构

华中科技大学同济医学院

[+1]

NCT07275827

/ Not yet recruiting临床3期IIT

Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection

this Study Evaluating Safety and Effectiveness of (Proton Pump Inhibitor versus Vonoprazan) Based Triple Therapy with or without Zinc to Eradicate H. pylori Infection

开始日期2026-02-01

申办/合作机构

Tanta University

100 项与 Zinc Sulfate Hydrate 相关的临床结果

登录后查看更多信息

100 项与 Zinc Sulfate Hydrate 相关的转化医学

登录后查看更多信息

100 项与 Zinc Sulfate Hydrate 相关的专利（医药）

登录后查看更多信息

3,476

项与 Zinc Sulfate Hydrate 相关的文献（医药）

2026-10-01·POULTRY SCIENCE

Bioavailability and growth performance of zinc sulfate, zinc glycinate, zinc amino acid hydrate, and zinc methionine hydroxy analog in male broilers

Article

作者: Mortada, Mohamad ; Hanson, Andrea ; Hickman, Jason ; Machens, Kelsey ; Charal, Jose ; Jones, Daniel ; Proctor, Rachel ; Ionescu, Catherine

Two experiments were conducted to evaluate the relative bioavailability (RBV) and performance effects of four zinc sources: zinc sulfate (ZnSO₄), zinc glycinate (ZnGly), zinc amino acid hydrate (ZnAAH), and zinc methionine hydroxy analog (ZnMHA) in male broilers. Experiment 1 used a depletion-repletion model with semi-purified diets to assess graded supplementation levels of ZnSO₄, ZnGly, and ZnAAH (0, 5, 10, 15, or 20 mg/kg). Experiment 2 evaluated all four sources at 10 and 60 mg/kg, along with a negative control (NC, 0 mg/kg), under practical corn-soybean meal feeding conditions. In Experiment 1, supplemental zinc significantly affected BWG, FI, FCR, and tibia zinc concentration. Growth responses (BWG and FI) exhibited both linear and quadratic trends, plateauing at approximately 11.7 mg/kg zinc intake, while tibia zinc increased linearly across all levels. Organic sources (ZnGly and ZnAAH) increased tibia zinc by 11-12% and improved FCR by 1.1-1.5 points compared with ZnSO₄. RBV estimates based on tibia zinc indicated that ZnGly and ZnAAH were 42-48% more bioavailable than ZnSO₄ (P < 0.05), with no significant differences between the two organic sources. In Experiment 2, zinc source influenced BWG, FI, and FCR (P < 0.05) and tended to affect overall FCR (P = 0.07). Supplementation with ZnSO₄ and ZnGly increased overall BWG by 118 g and 104 g, respectively, compared with NC, and resulted in greater performance than ZnMHA. ZnGly reduced overall FCR by 3.6 points, while ZnGly and ZnSO₄ improved adjusted FCR by 6.8 and 5.8 points, respectively, relative to NC (P < 0.05). ZnGly increased hot carcass yield by 0.62% (P < 0.05), whereas ZnSO₄ and ZnMHA showed trends toward improvement (P < 0.10). Excreta zinc increased with supplementation across all sources, while tibia zinc increased for all treatments except ZnMHA compared with NC. Overall, organic zinc sources demonstrated greater RBV than ZnSO₄ under semi-purified conditions, primarily based on tibia zinc responses. However, under practical feeding conditions, ZnSO₄ and ZnGly produced comparable improvements in growth performance, suggesting that RBV estimates may not fully predict performance outcomes in commercial-type diets. Future research should focus on optimizing zinc strategies to enhance carcass yield and explore broader physiological roles, including footpad health, immunity, welfare, and environmental sustainability in commercial broiler production.

2026-09-01·Advances in Medical Sciences

Liver-related autoantibodies in Wilson disease: increased prevalence and unclear clinical significance

Article

作者: Cudna, Agnieszka ; Misztal, Monika ; Litwin, Tomasz ; Antos, Agnieszka ; Niewada, Maciej ; Antczak-Kowalska, Magdalena ; Piechal, Agnieszka ; Członkowska, Anna

PURPOSE:

Wilson disease (WD) is a rare disorder of copper metabolism, primarily affecting the liver and brain. While the toxic effects of copper are well established, the role of autoantibodies in the disease's pathophysiology remains poorly understood. This study aimed to evaluate the prevalence of liver-related autoantibodies in WD patients and their associations with clinical manifestations.

MATERIALS AND METHODS:

A total of 112 patients with confirmed WD and 88 healthy volunteers were enrolled. Autoantibodies against liver-related antigens were measured in serum samples taken at diagnosis and during follow-up examinations using standardized Line Blot assays.

RESULTS:

Liver-related autoantibodies were detected more frequently in WD patients (39.3% at diagnosis and 42.9% at follow-up) than in controls (10.2%; both P ≤ 0.0001 versus controls). In particular, the frequency of antibodies to filamentous actin was significantly higher in WD patients (21.4% at diagnosis and 22.3% at follow-up) compared with healthy controls (2.3%; both P ≤ 0.0001 versus controls). The frequency of autoantibodies remained stable during treatment, regardless of whether D-penicillamine or zinc sulphate was used. There was no significant relationship between the presence of autoantibodies and biochemical markers of liver injury. Autoantibodies were more frequent in female patients, but their presence did not correlate with clinical manifestations or disease severity.

CONCLUSIONS:

Liver-related autoantibodies were frequently observed in WD and appeared to be markers of immune dysregulation. Further research is needed to clarify the clinical significance of these antibodies and their potential use as biomarkers in the management of WD.

2026-08-01·VETERINARY RESEARCH COMMUNICATIONS

Comparative evaluation of zinc hydroxychloride and zinc sulphate on growth performance, antioxidant status, immune function, and zinc bioavailability in growing crossbred calves

Article

作者: Sarkar, Srobana ; Tariq, Hujaz ; Mir, Shahid Hassan ; Sharma, Amit ; Mani, Veena ; Pal, Ravi Prakash

Zinc (Zn) is an essential trace mineral involved in antioxidant defense, immune regulation, and metabolic processes in livestock. Hydroxy trace minerals such as zinc hydroxychloride (ZnOHCl) have gained attention due to their greater ruminal stability and potentially higher bioavailability compared with zinc sulphate (ZnSO₄). This study evaluated the comparative effects of ZnOHCl and ZnSO₄ supplementation on growth performance, hemato-biochemical parameters, antioxidant status, immune response, and Zn bioavailability in growing crossbred calves. Twenty-four male calves were randomly allocated to four dietary treatments for 120 days: a basal diet without Zn supplementation, 80 mg Zn/kg DM as ZnSO₄, 40 mg Zn/kg DM as ZnOHCl, or 80 mg Zn/kg DM as ZnOHCl. Zinc supplementation, whether as ZnSO₄ or ZnOHCl, did not significantly affect the growth performance of calves. However, it significantly enhanced antioxidant enzyme activities, total antioxidant capacity, immunoglobulin concentrations, and both cell-mediated and humoral immune responses, while reducing lipid peroxidation (P < 0.05), with no significant differences were observed among the Zn-supplemented groups. Hemato-biochemical parameters were unaffected by Zn supplementation, except for increased plasma globulin concentration and alkaline phosphatase (ALP) activity, with no significant differences among Zn-supplemented groups. Zinc retention, along with plasma and erythrocyte Zn concentrations, increased significantly with Zn supplementation, with the highest retention observed in calves receiving 80 mg Zn/kg DM as ZnOHCl. Supplementation did not influence the retention or plasma concentrations of other minerals. Overall, Zn supplementation, irrespective of source or level, improved antioxidant status, immune function, and Zn retention in growing crossbred calves.

项与 Zinc Sulfate Hydrate 相关的新闻（医药）

2026-04-06

·drugs

Over 3 Million Eye Drops Recalled Amid Sterility Concerns

MONDAY, April 6, 2026 — More than 3 million bottles of over-the-counter eye drops are being recalled after officials raised concerns about the product's safety. The U.S. Food and Drug Administration (FDA) said the recall affects 3,111,072 bottles made by K.C. Pharmaceuticals of Pomona, California. The agency said the recall was issued due to a "lack of assurance of sterility," NBC News reported. The eye drops were sold under several names, including: Dry Eye Relief Eye Drops Dry Eye Relief Eye Drops Sterile Eye Drops Sterile Eye Drops Artificial Tears Sterile Lubricant Eye Drops Artificial Tears Sterile Lubricant Eye Drops They were available at major retailers such as CVS, Walgreens and Rite Aid, the FDA said. There have been no reports of injuries linked to the drops so far. The FDA classified this as a Class II recall, which means the products could cause temporary or medically reversible health problems. It’s not yet clear what caused the issue, either. The recall includes several types of 0.5-ounce (15 mL) bottles, NBC News reported. Among them: Sterile Eye Drops AC (tetrahydrozoline HCl 0.05%, zinc sulfate 0.25%), 0.5 fl oz (15 mL) bottles Sterile Eye Drops AC (tetrahydrozoline HCl 0.05%, zinc sulfate 0.25%), 0.5 fl oz (15 mL) bottles Sterile Eye Drops Original Formula (tetrahydrozoline HCl 0.05%), 0.5 fl oz (15mL) bottles Sterile Eye Drops Original Formula (tetrahydrozoline HCl 0.05%), 0.5 fl oz (15mL) bottles Sterile Eye Drops Redness Lubricant (glycerin 0.25% and naphazoline HCl 0.012%), 0.5 fl oz (15 mL) bottles Sterile Eye Drops Soothing Tears (polyethylene glycol 400 0.4% and propylene glycol 0.3%), 0.5 OZ 0.5 fl oz (15 mL) bottles Sterile Eye Drops Redness Lubricant (glycerin 0.25% and naphazoline HCl 0.012%), 0.5 fl oz (15 mL) bottles Sterile Eye Drops Soothing Tears (polyethylene glycol 400 0.4% and propylene glycol 0.3%), 0.5 OZ 0.5 fl oz (15 mL) bottles Dry Eye Relief Eye Drops, (glycerin 0.2%, hypromellose 0.2% and polyethylene glycol 400 1%) 0.5 fl oz (15 mL) bottles Dry Eye Relief Eye Drops, (glycerin 0.2%, hypromellose 0.2% and polyethylene glycol 400 1%) 0.5 fl oz (15 mL) bottles A complete list of affected drops and where they were sold is available on the FDA website. Sources NBC News, April 3, 2026 U.S. Food and Drug Administration, enforcement report, March 3, 2026

上市批准

2026-02-11

·GlobeNewswire-Health Care

Wesley Pharmaceuticals Launches NAD+, Introducing a Signature Longevity and Skin Health Formulation to Its Product Lineup

The premier 503B facility streamlines clinical access to its flagship NAD+ injection, offering an innovative wellness solution for Wesley’s nationwide client baseORLANDO, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Wesley Pharmaceuticals, a state-of-the-art 503B outsourcing facility, and sister brand of the nation’s leading 503A and 503B compounding pharmacy, Olympia Pharmaceuticals, today announced the launch of NAD+ (Nicotinamide Adenine Dinucleotide). A cornerstone of Olympia’s wellness portfolio, NAD+ is now available through Wesley to meet the growing demand for high-quality, longevity- and anti-aging-focused formulations. NAD Injections have long served as one of Olympia Pharmaceuticals’ flagship products, gaining widespread popularity for its Injectable and topical NAD+, NADvantage. By introducing NAD+ to the Wesley line, the company provides health care providers with a reliable, 503B-compliant source. The new product is available in a 100mg/mL concentration and is designed for versatile clinical administration via intravenous (IV), intramuscular (IM) or subcutaneous (SubQ) injection. Olympia’s NAD+ is available for purchase in combination with Sermorelin, a synthetic version of the naturally occurring growth hormone-releasing hormone (GHRH) produced in the pituitary gland. This pairing is designed to optimize metabolic health and cellular longevity. Additionally, Sermorelin is featured in several of Olympia’s weight management kits for patients focused on fitness and weight loss. “NAD+ is the gold standard for those pursuing advanced wellness,” said Stan Loomis, co-founder of Olympia and Wesley Pharmaceuticals. “By bringing this formulation to Wesley, we are meeting the high demand from our partners and consumers for a product that combines Olympia's exceptional quality with Wesley’s specialized outsourcing standards.” Naturally occurring in all living cells, NAD+ is a critical cofactor that enhances mitochondrial function, serving as the primary fuel for the intracellular energy powerhouses that convert micronutrients into ATP and support DNA repair. Wesley has designed the product with durable vials made from advanced glass to minimize breakage and enhanced packaging for improved clinical accessibility. When administered via infusion or injection, compounded NAD+ may improve mental clarity, memory, and alertness while supporting athletic endurance, addressing symptoms of chronic fatigue, and improving skin tone. “Wesley Pharmaceuticals was built on an engineering mindset and finding ways to make great products even better,” said Naomi Loomis, co-founder of Olympia and Wesley Pharmaceuticals. “Bringing our premier product into the Wesley family allows us to offer our clients more choices and the same trusted quality they expect from our comprehensive wellness ecosystem.” This announcement follows Wesley’s successful debut of Zinc Sulfate in 2025. NAD+ is available exclusively to Olympia clients who are located in eligible states and have updated their required 503B paperwork. Wesley is currently licensed in 29 states, with further expansions expected throughout 2026. To determine eligibility, clients can visit the Wesley license tracker here. For physicians and providers interested in opening an account with Olympia and Wesley, please visit https://www.olympiapharmacy.com/contact/. About Wesley PharmaceuticalsWesley Pharmaceuticals, a sister brand of Olympia Pharmaceuticals, was co-founded by Stan and Naomi Loomis in 2024 in honor of Wesley Loomis, their son and a beloved team member. Based in Orlando, Florida, the company plans to deliver high-quality compounded medications across therapeutic areas, including weight management, IV nutritional therapy, and wellness. Rooted in compassion and patient-first care, Wesley is dedicated to supporting pharmacies and providers with innovative solutions that improve lives. About Olympia PharmaceuticalsOlympia Pharmaceuticals is a state-of-the-art, FDA-registered 503B pharmaceutical outsourcing facility and 503A pharmacy supporting both patient-specific and office-use needs across the U.S. Co-founded by Stan and Naomi Loomis, the team is made up of pharmacy technicians, pharmacists, quality personnel, and engineers, creating an educated and experienced staff knowledgeable in all facets of pharmacy production. As an FDA-registered outsourcing facility, Olympia offers compounded medications to 49 states for both office use and patient prescriptions. Olympia specializes in weight loss, dermatology, IV nutritional therapy, erectile dysfunction, and more. Media ContactDaniele SpringUproar by Moburst for Olympia and Wesley PharmaceuticalsDaniele.Spring@Moburst.com

2025-12-03

·GlobeNewswire-Health Care

Wesley Pharmaceuticals Unveils First Product, Zinc Sulfate, Revolutionizing Wellness Solutions

Debut product from the innovative 503(b) outsourcing facility delivers enhanced wellness to Olympia Pharmaceutical clients, marking a new era of innovationORLANDO, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Wesley Pharmaceuticals, a state-of-the-art 503(b) outsourcing facility and sister brand of the nation’s leading 503A and 503B compounding pharmacy, Olympia Pharmaceuticals, is proud to announce the launch of its first product, Zinc Sulfate, marking a significant milestone for the company. Wesley Pharmaceuticals has designed Zinc Sulfate with several upgrades to improve both product accessibility and durability. The product features a new flip-top cap for easier opening, durable vials made from advanced glass to minimize breakage, and a modern label design that reflects Wesley’s innovative approach. The product is available in a 10mg/mL concentration with a 10mL volume fill, priced in line with Olympia's offerings with no additional shipping fees. “We are honored to introduce Wesley’s first product,” said Stan Loomis, co-founder of Olympia and Wesley Pharmaceuticals. “This milestone reflects our commitment to delivering high-quality, innovative solutions for those seeking trusted wellness products.” Zinc Sulfate is an essential mineral vital for overall wellness, supporting immune function and wound healing. It helps the body fight infections, repair tissues and maintain healthy skin. As one of Olympia’s top-moving products, Zinc Sulfate is especially in demand during the height of the cold and flu season, making it a timely release for Wesley Pharmaceuticals. Zinc also plays a role in hormonal balance, with research suggesting potential benefits for supporting testosterone levels and sexual function in postmenopausal women. Additional formulations, such as NAD+, glutathione, and B-complex, are also planned for launch by Wesley Pharmaceuticals during the first quarter of 2026. “Our team at Olympia has worked tirelessly to uphold the highest standards of quality in every product produced under the Wesley Pharmaceuticals name,” said Naomi Loomis, co-founder of Olympia and Wesley Pharmaceuticals. “Our focus on honoring Wesley’s legacy is reflected in our effort to provide Olympia clients with the choice of two trusted brands.” Named in honor of Wesley Loomis, a beloved family member and talented sterile compounding technician at Olympia, Wesley Pharmaceuticals represents his inventive spirit and engineering mindset. The brand’s sleek design, incorporating black, Wesley’s favorite color, pays tribute to his legacy and creativity. Wesley Pharmaceuticals products are available exclusively to Olympia clients who have updated their paperwork and are located in eligible states. Wesley is currently licensed in 21 states, with additional approvals pending. To determine eligibility, clients can visit the Wesley license tracker here. For physicians and providers who would like to open an account with Olympia and Wesley, please visit https://www.olympiapharmacy.com/contact/. About Wesley PharmaceuticalsWesley Pharmaceuticals, a sister brand of Olympia Pharmaceuticals, was co-founded by Stan and Naomi Loomis in 2024 in honor of Wesley Loomis, their son and a beloved team member. Based in Orlando, Florida, the company plans to deliver high-quality compounded medications across therapeutic areas, including weight management, IV nutritional therapy, and wellness. Rooted in compassion and patient-first care, Wesley is dedicated to supporting pharmacies and providers with innovative solutions that improve lives. About Olympia PharmaceuticalsOlympia Pharmaceuticals is a state-of-the-art, FDA-registered 503B pharmaceutical outsourcing facility and 503A pharmacy supporting both patient-specific and office-use needs across the U.S. Co-founded by Stan and Naomi Loomis, the team is made up of pharmacy technicians, pharmacists, quality personnel, and engineers, creating an educated and experienced staff knowledgeable in all facets of pharmacy production. As an FDA-registered outsourcing facility, Olympia offers compounded medications to 49 states for both office use and patient prescriptions. Olympia specializes in weight loss, dermatology, IV nutritional therapy, erectile dysfunction, and more. Media ContactDaniele SpringUproar by Moburst for Olympia and Wesley PharmaceuticalsDaniele.Spring@Moburst.com

100 项与 Zinc Sulfate Hydrate 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01081	-	A12CB01	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
膳食补充剂	美国	Abraxis Pharmaceutical Products	1987-05-05
睑缘炎	日本	Santen Pharmaceutical Co., Ltd.	1969-10-29
结膜炎	日本	Santen Pharmaceutical Co., Ltd.	1969-10-29
角膜溃疡	日本	Santen Pharmaceutical Co., Ltd.	1969-10-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床前	中国	华中科技大学医院	2008-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03158168 (Pubmed \| Arch Klin Exp Dermatol)	临床3期	疣	-	Intralesional Candida antigen 1/100	艱壓願齋蓋築鹹築窪觸(網製窪遞獵鬱壓艱齋襯) = 蓋構構選糧鹽窪襯憲觸鹹網製範願積壓顧製糧 (醖選醖觸願製蓋範選衊 )	积极	2022-12-26
				Intralesional Candida antigen 1/1000	艱壓願齋蓋築鹹築窪觸(網製窪遞獵鬱壓艱齋襯) = 簾構糧製製膚齋艱艱鏇鹹網製範願積壓顧製糧 (醖選醖觸願製蓋範選衊 )
NCT01198587 (CTgov)	N/A	胃肠炎 \| 急性腹泻	71	Zinc Sulfate (Outpatient Zinc Sulfate)	繭衊憲鏇顧衊窪蓋簾觸(觸蓋願夢壓簾餘鹹製襯) = 範齋遞齋範構網構觸獵鬱壓選鏇範糧鏇淵繭衊 (鹽鬱壓艱齋製積蓋顧壓, 77.8) 更多	-	2018-08-22
				Zinc Sulfate (Inpatient Zinc Sulfate)	繭衊憲鏇顧衊窪蓋簾觸(觸蓋願夢壓簾餘鹹製襯) = 鬱觸憲鏇網鹽鹹築繭簾鬱壓選鏇範糧鏇淵繭衊 (鹽鬱壓艱齋製積蓋顧壓, 78.7) 更多
NCT00395226 (CTgov)	N/A	玫瑰痤疮	65	zinc sulfate	製糧繭遞選艱範遞衊艱(築襯繭醖廠餘繭鹹膚範) = 膚範積構淵構觸憲衊糧繭蓋憲簾蓋構選遞醖簾 (蓋觸憲襯製鬱餘窪窪鹽, 顧廠積齋鏇壓繭鑰鑰網 ~ 構糧壓鏇鑰網獵積醖鹹) 更多	-	2011-06-30
NCCTG (ASTRO2006)	N/A	头颈部肿瘤	169	Zinc Sulfate 45 mg	鬱鏇顧鑰憲鑰鏇齋觸範(鬱繭壓艱製觸廠憲網衊) = 製鑰衊願簾憲壓製網窪鑰繭壓鏇糧鹽窪觸鏇願 (齋觸蓋鹹廠鏇衊廠鹽壓 ) 更多	不佳	2006-11-01
				Placebo	鬱鏇顧鑰憲鑰鏇齋觸範(鬱繭壓艱製觸廠憲網衊) = 憲簾觸鹽衊餘獵範齋艱鑰繭壓鏇糧鹽窪觸鏇願 (齋觸蓋鹹廠鏇衊廠鹽壓 ) 更多